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DDiscussion
Dr D. Craig Miller (Stanford, Calif). Joe, that was perfect.
Crisp and quick. I want to thank you because I believe I heard
the term ‘‘Stanford type A’’ once. Appreciate that.
Dr Coselli. You’re welcome.
Dr Miller. We have several balls, or unanswered questions, in
the air here. The simplest question actually is probably the one
you answered today. We know the numerator consisting of the
number of people who required another downstream operation,
and you have shown clearly using modern open surgical tech-
niques that the risk of these reoperations is low and the 5-year
durability is reasonable. Eric Roselli, the late Roy Greenberg,
Lars Svensson, and the Cleveland Clinic group have shown that
endovascular TEVAR or open surgical repair of descending aortic
chronic dissections is associated with a similarly low operative risk
and similar short-term outcomes. Not to get sidetracked, whether
TEVAR is effective treatment for chronic dissections of the DTA
is a separate, controversial topic begging for the proper random-
ized prospective clinical trial. Nonetheless, we all can agree on
the answer to the first question: When necessary, surgical repair
of the downstream descending or thoracoabdominal chronic aortic
dissection in experienced, high-volume centers is relatively safe
and efficacious.
The bigger unanswered question is what is the denominator?
We need this number to estimate how many patients surviving
an acute type A dissection eventually need something done down-
stream and characterize which patients are at higher risk of reop-
eration, for example, possibly those with a connective tissue
disorder, to learn what can we do at the first operation to reduce
the incidence of late reoperation and sudden, unexplained late
deaths. You mentioned that some of these patients die later on
and some may die of downstream aortic complications because
they did not undergo reoperation, an area ripe for potential
improvement.
So what we can do better during the initial acute dissection
operation in patients who are at higher risk for subsequent down-
stream aortic false lumen enlargement of the thoracoabdominal
chronic dissection? Dr Kazui in Japan (eg, total arch replacement
in selected patients with theMarfan syndrome), Daniel Loisance at
the Hospital Mo^ndor in Paris, and Marc Moon at Washington
University have analyzed if performing a more radical operation
the first time reduces the need for subsequent downstream
reoperation, but none have shown success. As exemplified by the
report from Paris by Loisance and colleagues, the incidence of
reoperation paradoxically increases over time because ourThe Journal of Thoracic and Carthreshold to do something downstream declines over the years,
that is, our indications for reintervention become more aggressive.
So, we have a ‘‘moving goal posts’’ problem, which makes it tough
to answer this question short of a randomized prospective clinical
trial.
Nonetheless, you mentioned adding a stent-graft or FET in the
DTA at the time of the initial acute dissection operation. This
seems to be the most popular technique being tried now, as your
Baylor team, Eric Roselli at the Cleveland Clinic, Alberto Pochet-
tino and others in the United States, several European groups, and
Dr Sun in Beijing often place a standard stent-graft into the distal
end of the replacement graft, but in Europe a specialty hybrid de-
vice (an open replacement graft combined with a stent-graft) is
placed in the true lumen of the proximal DTA during the initial
emergency arch/ascending aortic replacement hoping to reduce
the incidence of late downstream false aneurysmal degeneration
and need for reoperation.
How are we going to sort out whether a more radical approach
like this at the time of the initial operation—and in which patients
it is needed—is justified without knowing the denominator and
given the fact that our reintervention endpoints are changing
over time? As you yourself have stated, any time you do something
beyond the left subclavian at the time of the first operation for
acute type A dissection you add incremental risk, namely, the
risk of paraplegia. Further, the new German GERAADA registry
data demonstrate that if one replaces the arch when you otherwise
would not have to, you increase the early acute type A dissection
operative mortality rate by 10% in Germany. How do we sort out
this conundrum? Who is going to pay for the randomized clinical
trial that is obviously required?
Dr Coselli. Well, thank you, Dr Miller. I don’t have an answer
for this conundrum, and the fact that you don’t either is probably
why it remains a conundrum. Clearly in this work, we are dealing
with the numerator and not the denominator, and, as at most of our
institutions, many of these patients come from far and wide and are
extremely difficult to follow up. So, determining the denominator
is challenging.
You are absolutely right. When we have tried an expanded
approach to repair at the initial operation, with an aim to reduce
the likelihood of a second operation, we do that at a price.
Expanded approaches have included total arch replacement, and,
as you mentioned, the operation de jour, which is to place a stent
graft in the true lumen at the initial procedure. These approaches
increase early risk; as you mentioned from the German Registry
for Acute Aortic Dissection Type A (GERAADA) study, the total
arch approach carries a 10% risk in mortality, and in the latter there
is a risk of paraplegia. But trying to balance out these initial mor-
bidities and mortalities with what is best in the long term is what
we are trying to establish. Such work would give us a benchmark
by which to compare these other techniques, both in the short term
and the long term, but a great deal morework is going to have to be
done to sort this out.
Dr E. Roselli (Cleveland, Ohio). My question is about the fate
of the aortic arch. I noted that you reoperated on 7 of those. Were
those patients who had the reverse elephant trunk technique,
numbers 1 and 2, the ones in whom the native arch was left behind,
was that chronically dissected, and how do you make the decision
about how to operate on that intervening segment?diovascular Surgery c Volume 148, Number 6 2993
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DDr Coselli. For the last part, the decision to operate on the arch
is primarily determined by the rate of increase in size, the develop-
ment of symptoms, and the absolute size, using approximately 6 to
6-1/2 cm diameter in that particular location. All of the patients in
this group had chronic dissection of the transverse aortic arch. As2994 The Journal of Thoracic and Cardiovascular Surwe all well know, the arch is usually the last thing to dilate.
This adds to the discussion about how aggressive to be at the
initial operation, and only a couple of patients in this series have
returned for arch repair after undergoing a reverse elephant trunk
procedure.gery c December 2014
